The current price offers a great entry point, says the team, led by Jeffrey Holford, upgrading to Buy with price target lifted to $108 from $102.
Execution in pharmaceuticals remains strong and will be supplemented by new "underappreciated" launches like Imbruvica.
The consumer division should be in recovery mode now that manufacturing issues are in the rear-view mirror. The MD&D division looks good thanks to the Synthes acquisition.
Valuation - a 2% premium to the board market based on 2015 estimates - looks particularly cheap to the team, as JNJ typically rates a 10-15% premium.